Health technology developers face stricter pre-market approval workflows following updated FDA recommendations for adaptive medical software. Regulators now require software-as-a-medical-device (SaMD) vendors to demonstrate algorithmic consistency across varied demographic data sets.
Post-Market Surveillance
Hospitals must implement continuous audit pipelines to detect potential model degradation over time. The added compliance overhead is expected to extend product launch cycles for clinical decision support tools by six to nine months.